ANNUAL REPORT 2026GLOBAL LEADER IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASESMESOBLAST LIMITED ANNUAL REPORT 2026CORPORATE GOVERNANCEMesoblast Limited and its Board of Directors are committed to implementing and achieving an e?ective corporate governance framework to ensure that the...